Das Mamali, Kiruthiga Chandramohan, Shafreen R Beema, Nachammai Kathiresan, Selvaraj Chandrabose, Langeswaran K
Department of Biomedical Science, Alagappa University, Karaikudi, 630003, India.
Department of Biotechnology, Alagappa University, Science Campus, Karaikudi, Tamil Nadu, India.
Eur J Pharmacol. 2025 Jun 5;996:177436. doi: 10.1016/j.ejphar.2025.177436. Epub 2025 Feb 27.
The integration of microbiome research and nanotechnology represents a significant advancement in immuno-oncology, potentially improving the effectiveness of cancer immunotherapies. Recent studies highlight the influential role of the human microbiome in modulating immune responses, presenting new opportunities to enhance immune checkpoint inhibitors (ICIs) and other cancer therapies. Nanotechnology offers precise drug delivery and immune modulation capabilities, minimizing off-target effects while maximizing therapeutic outcomes. This review consolidates current knowledge on the interactions between the microbiome and the immune system, emphasizing the microbiome's impact on ICIs, and explores the incorporation of nanotechnology in cancer treatment strategies. Additionally, it provides a forward-looking perspective on the synergistic potential of microbiome modulation and nanotechnology to overcome existing challenges in immuno-oncology. This integrated approach may enhance the personalization and effectiveness of next-generation cancer treatments, paving the way for transformative patient care.
微生物组研究与纳米技术的整合代表了免疫肿瘤学的一项重大进展，有可能提高癌症免疫疗法的有效性。最近的研究突出了人类微生物组在调节免疫反应中的重要作用，为增强免疫检查点抑制剂（ICI）及其他癌症疗法带来了新机遇。纳米技术具备精确的药物递送和免疫调节能力，可将脱靶效应降至最低，同时使治疗效果最大化。本综述整合了关于微生物组与免疫系统相互作用的现有知识，强调了微生物组对ICI的影响，并探讨了纳米技术在癌症治疗策略中的应用。此外，它还对微生物组调节与纳米技术协同克服免疫肿瘤学现有挑战的潜力提供了前瞻性观点。这种综合方法可能会提高下一代癌症治疗的个性化程度和有效性，为变革性的患者护理铺平道路。
